2. Academic Validation
  3. Thermosensitive nanogel-based oxaliplatin delivery system for synergistic intratumoral radiofrequency chemotherapy

Thermosensitive nanogel-based oxaliplatin delivery system for synergistic intratumoral radiofrequency chemotherapy

  • Biomater Adv. 2026 May:182:214726. doi: 10.1016/j.bioadv.2026.214726.
Ling Li 1,  Anna Liu 2,  Cai Wang 1,  Ling Zhang 1,  Houqiang Yu 3,  Han Li 4,  Hongfu Zhou 5
Affiliations

Affiliations

  • 1 School of Biomedical Engineering and Imaging, Xianning Medical College, Hubei University of Science and Technology, Xianning, 437100, China.
  • 2 School of Biomedical Engineering and Imaging, Xianning Medical College, Hubei University of Science and Technology, Xianning, 437100, China; School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, 437100, China.
  • 3 Department of mathematics and statistics, Hubei University of Science and Technology, Xianning 437100, China. Electronic address: [email protected].
  • 4 Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, China. Electronic address: [email protected].
  • 5 School of Biomedical Engineering and Imaging, Xianning Medical College, Hubei University of Science and Technology, Xianning, 437100, China; Hubei Key Laboratory of Processing and Application of Catalytic materials, Huanggang Normal University, China. Electronic address: [email protected].
PMID: 41581319 DOI: 10.1016/j.bioadv.2026.214726
Abstract

To achieve sustained release and prolonged tumor retention of oxaliplatin (OXA), a thermosensitive OXA-loaded poly(N-isopropyl acrylamide-co-acrylic acid) nanogel (PAAs) was developed via a synergistic mixing-stirring method. The formulation, consisting of 0.8 mg/mL OXA thoroughly dispersed in 8% poly(N-isopropyl acrylamide-co-acrylic acid) nanogel (PNAs), exhibited favorable radiofrequency responsiveness, thermosensitivity, and controlled-release properties, enabling continuous OXA release for up to five days. The sol-gel phase transition behavior of the thermosensitive PAAs nanogel was characterized using the vial-inversion method and rheological analysis. Platinum content analysis revealed enhanced tumor retention of the PAAs nanogel compared with free OXA, as evidenced by significantly higher platinum levels in tumors treated with the nanogel formulation. In vivo antitumor efficacy evaluation demonstrated that a single administration of the PAAs nanogel resulted in sustained tumor regression, reducing the relative tumor volume to 0.81 ± 0.06 times the initial volume within 14 days. In contrast, treatment with an equivalent dose of free OXA, PNAs alone, or normal saline led to rapid tumor progression, with tumor volumes increasing to 3.22 ± 0.65, 7.01 ± 0.47, and 10.07 ± 1.57 times the initial volume, respectively. Preliminary biocompatibility assessment indicated that the incorporation of OXA into PNAs within the nanogel significantly alleviated the toxic side effects associated with free OXA. These findings underscore the considerable potential of the PAAs nanogel as a versatile strategy to enhance the antitumor efficacy of platinum-based drugs while mitigating their systemic toxicity and size-related limitations. This system therefore represents a promising candidate for further development as a novel nanomedicine for localized chemotherapy.

Keywords

Intra tumoral injection; Oxaliplatin; Radiofrequency thermal responsiveness; Thermosensitive nanogels.

Figures
Products